Anemia is a most common hematologic disorder in majority of cancer patients receiving chemotherapy treatment. Anemia is a condition in which person do not have sufficient red blood cells in the body or low ability of hemoglobin to carry oxygen and circulate it to all cells in the body. Anemia can be caused by cancer treatment, low iron levels in body, organ problems, chronic kidney disease and thalassemia. Moreover, some other risk factors that can develop anemia among cancer patients are namely platinum based chemotherapy, low level of red blood cells before having cancer and certain tumor type. To find out the cause of anemia certain tests need to be done such as blood chemistry tests, reticulocyte count, stool test and bone marrow exam. In Europe, the study has been conducted by European Cancer Anemia Survey (ECAS) across 24 nations stated that around 83% of the patients going for chemotherapy demonstrated anemia disorder. Anemia often exhibit symptoms such as fatigue, dyspnea, chest pain and fast heartbeat. It has been estimated that about 50% of the cancer patients suffering from anemia did not received any treatment. However, patients with head and neck cancer suffering from anemia have risk of death is around 19% and 47% with prostate cancer patients.
Chemotherapy Induced Anemia Market:Drivers and Restraints
Chemotherapy induced anemia market are witnessing maximum growth owing to increase in the prevalence of cancer and anemia among geriatric patients, bone marrow invasion, increase in pipeline products, advancement in the technology, reimbursement policy and increase in chronic inflammatory conditions. Moreover, side effects of the cancer treatment can develop anemia and increase in various etiologies of anemia in cancer patients are some other factors expected to flourish the chemotherapy induced anemia market. However, side effects of drugs, increase in the mortality rate and risk associated with treatment may hamper the growth of chemotherapy induced anemia market in near future.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1757
Chemotherapy Induced Anemia Market:Segmentation
The chemotherapy induced anemia market has been classified on the basis of range of anemia, treatment type, drug type and end user.
Based on rang of anemia, the chemotherapy induced anemia market is segmented into the following:
- Mild Anemia
- Moderate Anemia
- Severe Anemia
- Life-threatening Anemia
Based on treatment type, the chemotherapy induced anemia market is segmented into the following:
- RBC Transfusions
- Erythropoiesis-stimulating agents (ESAs)
- Iron Supplementation
Based on drug type, the chemotherapy induced anemia market is segmented into the following:
- Epogen Injection
- Procrit Injection
- Androxy Oral
- Aranesp injection
- Epoetin Alfa Injection
Based on end-user, the chemotherapy induced anemia market is segmented into the following:
- Ambulatory Surgical Centers
- Multispecialty Clinics
- Cancer Research Centers
- Cancer Rehabilitation Centers
Chemotherapy Induced Anemia Market:Overview
In Japan, cancer patients with anemia disorder are treated with RBC transfusions. On the other hand, in USA and Europe patients with chemotherapy induced anemia are treated with erythropoiesis stimulating agents namely epoetin & darbepoetin. Fatigue is the most severe symptoms of chemotherapy induced anemia among cancer patients and experience fatigue in moderate to severe range of anemia. Patients received platinum, gemcitabine and anthracycline based regimens has high chances of develop anemia.
Chemotherapy Induced Anemia Market: Region-wise Outlook
Depending on geographic region, Chemotherapy Induced Anemia Market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa. Asia Pacific dominates the chemotherapy induced anemia marketfollowed by Europe, Japan and North America owing to high awareness of disease among population, government initiatives, great advancement in the field of chemotherapy induced anemia and developed healthcare infrastructure in these regions. Asia Pacific, Middle East and Africa hold huge potential and shows substantial growth in terms of wide acceptance of new technologyowing to high mortality rate, prevalence of anemia among cancer patients, increasing healthcare expenditure and high potential customer base need treatment for chemotherapy induced anemia.
Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1757
Chemotherapy Induced Anemia Market:Key Players
Key players of Chemotherapy Induced Anemia Marketare Dr. Reddy’s Laboratories Ltd., Pfizer Inc., SBI Pharmaceuticals Co., Ltd, Panacea Biotec Limited, Panacea Biotec., 3SBio Inc., Tolero Pharmaceuticals, Inc., Vifor Pharma AG and Therapure Biopharma Inc.